HTLV, Immunoblot, Human


HTLV Blood Screening & Confirmation

HTLV screening of blood donor samples for transfusion-transmissible infections is recommended by the World Health Organization (WHO) for the provision of safe blood products, and is supported by the Centers for Disease Control and Prevention (CDC) and the Global Virus Network (GVN) HTLV Task Force. Our highly sensitive HTLV I/II ELISA 4.0 enables your lab to screen blood donors with great confidence. Trust our assays to ensure confidence in the safety of your blood supply and reduce HTLV transmission through blood transfusion.

Reliable HTLV Confirmation and Donor Typing

The HTLV Blot 2.4 is intended for the in vitro detection of antibodies to HTLV-I and HTLV-II in human serum or plasma, as a more specific supplemental test on donor specimens found repeatedly reactive using screening procedures. It delivers outstanding performance with a combination of HTLV-I viral proteins and patented recombinant proteins from HTLV-I and HTLV-II. Together, the HTLV I/II ELISA 4.0 and HTLV Blot 2.4 help to support the global efforts to eradicate HTLV.

  • The only HTLV confirmatory test with both FDA approval and CE Mark for blood donor specimens
  • Differentiates HTLV-I and HTLV-II
  • Enhanced sensitivity and specificity with unique group-specific and type-specific recombinant envelope proteins
  • Rapid assay time (< 3.5 hours)
  • Simple methodology using western blot technology
  • Option to automate your assay using FDA-validated Autoblot 20
2 Results Found

Active filters:

  • Diagnostic Platforms:
  • Species Reactivity:
  • Clear All

HTLV Blot 2.4 (FDA)

The MP Diagnostics HTLV Blot 2.4 is intended as a supplemental (additional more specific), test to confirm the presence of anti-HTLV-I/II antibodies in blood donor specimens repeatedly reactive on an FDA licensed screening test and to differentiate between HTLV type-I and HTLV type-II infections for donor notification and counseling. The possible serological profiles defined by the HTLV Blot 2.4 include the following: HTLV-I Seropositive, HTLV-II Seropositive, HTLV-I/II Seropositive, Seronegative and Indeterminate. The MP Diagnostics HTLV Blot 2.4 uses a combination of HTLV-I/II genetically engineered proteins (i.e., recombinant antigens) and HTLV-I viral proteins derived from native, inactivated viral particles (i.e., viral lysate). The differentiation between HTLV-I and HTLV-II is accomplished through the use of rgp46-I, a unique HTLV-I envelope recombinant protein, and rgp46-II, a unique HTLV-II envelope recombinant protein. Both proteins are derived from the central region of the external glycoprotein, gp46, of HTLV-I and HTLV-II respectively. GD21, a common yet specific HTLV-I and HTLV-II epitope envelope recombinant protein derived from a truncated region of p21e (rgp21), is also used to enhance the specificity of envelope antibody detection: GD21 has demonstrated better specificity over p21e73, an earlier version of the recombinant antigen. The antigenicity exhibited by these recombinant proteins is either common to HTLV-I and HTLV-II antibodies or type specific to one of the two viral types to allow confirmation and differentiation in a single assay. Additional differentiation between HTLV viral types is effected using gag proteins p19 and p24; if p19 is greater than or equal to p24, HTLV-I infection is suggested, and if p24 is greater than p19, HTLV-II infection is suggested.

HTLV Blot 2.4 (CE)

The MP Diagnostics HTLV BLOT 2.4 is a qualitative enzyme immunoassay for the in vitro detection of antibodies to HTLV-I and HTLV-II in human serum or plasma. It is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures like the Enzyme-Linked Immunosorbent Assays (ELISA).

  • 1